Latest news with #MarianaChavezMacGregor
Medscape
24-06-2025
- Health
- Medscape
Integrating ASCO 2025 Insights in Early-Stage Breast Cancer
Mariana Chavez MacGregor, MD, reflects on the 2025 ASCO Annual Meeting and its immediate impact on her clinical practice, particularly for patients with early-stage breast cancer. She describes applying findings from the neoCARHP study to personalize treatment for a patient with HER2-positive disease by safely omitting carboplatin to reduce toxicity. She also emphasizes the importance of addressing sexuality in cancer survivorship, empowered by educational sessions that offered practical ways to initiate these sensitive conversations. Finally, Dr Chavez MacGregor highlights a plenary session on structured exercise improving survival in colorectal cancer survivors, reinforcing how lifestyle interventions can enhance both quality of life and outcomes across oncology care.
Medscape
09-06-2025
- Health
- Medscape
ASCO 2025: Key Updates in Early Breast Cancer Care
Mariana Chavez MacGregor, MD, MSc, comments on how the ASCO 2025 meeting delivered a wealth of impactful data, particularly in the early-stage breast cancer setting. Trials like neoCARHP and CompassHER2 raised important questions about de-escalating therapy for HER2-positive patients, challenging the role of carboplatin and demonstrating strong pathologic complete response rates with shorter regimens. Long-term data from SOFT and TEXT reinforced the survival benefits of ovarian suppression plus an aromatase inhibitor in high-risk premenopausal patients, and the OASIS 4 study showed promise with elinzanetant in managing vasomotor symptoms. Across subtypes, including triple-negative disease, and with the growing role of AI and circulating tumor DNA, the meeting emphasized more personalized, less toxic approaches to care.
Medscape
22-05-2025
- Health
- Medscape
ASCO 2025: Previewing Updates in Early-Stage Breast Cancer
Mariana Chavez MacGregor, MD, MSc, shares her enthusiasm for the 2025 ASCO Annual Meeting, particularly for its relevance to early-stage breast cancer. She highlights key sessions focused on treatment optimization and de-escalation for HER2-positive patients, along with important updates on the management of HR-positive breast cancer in premenopausal women, including the SOFT, TEXT, and ASTRRA trials. Dr Chavez MacGregor also points to new research on elinzanetant for managing vasomotor symptoms associated with endocrine therapy. Additionally, she is eager to attend the Dr Bernard Fisher Memorial Annual Clinical Science Symposium, which will explore circulating tumor DNA and its role in monitoring early-stage breast cancer.
